OnabotulinumtoxinA 100 UNT
Phase 3Small molecule
OnabotulinumtoxinA 100 UNT is one of 10 small molecule programs targeting Trigeminal Neuralgia. It is currently in Phase 3.
2
Indications
6
Total Trials
3
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
13 competitors in Trigeminal Neuralgia
#DrugCompanyPhaseTrials
1Tegretol
NovartisApproved
Trileptal
NovartisApproved
Xylocaine
MMEDRx USA, Inc.
Approved
Lamictal
GGlaxo Dba Glaxosmithkline
Approved
Intuniv
PPromius Pharma, LLC
Approved
Basimglurant
RochePhase 3
OnabotulinumtoxinA 100 UNT
SStanford University
Phase 3
Vimpat
UCBPreclinical
Alloex
TThe Foundation for Orthopaedics and Regenerative Medicine
Phase 1
Cerebyx
LLupin Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Botulinum Toxin1 trial
1 more indication
Urgency Urinary Incontinence1 trial
Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence
Active, not recruiting·WWomen and Infants Hospital of Rhode Island·Approved·NCT05806164·432 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for OnabotulinumtoxinA 100 UNT. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- SStanford University